1st May 2008 07:00
Tepnel Life Sciences PLC01 May 2008 FOR IMMEDIATE RELEASE Tepnel's preferred supplier agreement with AstraZeneca for DNA extractionservices is extended Manchester, UK, 1 May 2008 - Tepnel Life Sciences PLC (AIM: TED), the UK-basedinternational Molecular Diagnostics and Research Products & Services group,announced today it has extended its global Master Services Agreement withAstraZeneca, one of the world's leading pharmaceutical companies. Under the terms of this agreement Tepnel will continue to act as a preferredsupplier to AstraZeneca for DNA extraction services. By continuing to provide ahigh quality service in the market, Tepnel will have the opportunity to competefor further business with AstraZeneca at volume-related discounts. Ben Matzilevich, CEO, commented: "Following our very strong financial resultsfor 2007 we are delighted to announce the extension of our existing agreementwith AstraZeneca. "Tepnel has been a supplier to AstraZeneca in the area of DNA extraction for anumber of years and this announcement is evidence of the high level of clientservice and technical expertise that we are able to deliver. This agreementfurther strengthens Tepnel's position in the pharmaceutical industry as one ofEurope's largest providers of DNA extraction services." - ends - Enquiries: Tepnel Life Sciences plcBen Matzilevich, CEO 0161 946 2200 Capital MS&L Mary Clark or Joey Whineray +44 207 307 5330 Seymour Pierce LimitedMark PercyTel: +44 20 7107 8000 Notes to Editors About Tepnel Life Sciences plc Tepnel Life Sciences (AIM:TED) is a UK-based international life sciencesproducts and services Group with two divisions, Molecular Diagnostics andResearch Products & Services. The Company has laboratories, manufacturing andoperations in the USA, UK and France with over 200 employees. Tepnel providestest kits, reagents and services to two highly synergistic markets, these beingMolecular Diagnostics and Biomedical Research. The Company's strategy has beento identify high growth niche opportunities within these multi-billion poundmarkets. Tepnel focuses on these niche operations with internally developedproducts, patents, expertise and know-how as well as strategic acquisitions, todevelop a leadership position within these defined market segments. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
TED.L